CAR-T Therapies: Improving on Today’s Reality and Planning for Tomorrow’s Innovation

Posted by Sharon Karlsberg on Jul 5, 2018 8:00:00 AM

Katie Blodgett and Robert Rovner co-authored this post with Sharon Karlsberg. 

Adoptive cell immunotherapy got top billing at this year’s American Society of Clinical Oncology (ASCO) meeting with its designation as the 2018 clinical cancer “Advance of the Year,” and for good reason. The first generation of chimeric antigen receptor T-cell (CAR-T) therapies, set in motion with the late 2017 approvals of Kymriah (Novartis) and Yescarta (Kite, a Gilead company), are among the most anticipated cancer breakthroughs to date.


>
Read More

A New Era of Biosimilars in Oncology: Four Themes From ESMO 2017

Posted by Christina Corridon on Sep 21, 2017 12:30:53 PM

The European healthcare landscape has more than a decade of in-market experience with supportive care biosimilars. However, we’re entering a new era for biosimilars in oncology with the recent launch of therapeutic biosimilars in the EU.

At the recent European Society for Medical Oncology (ESMO) Congress, held Sept. 8-12 in Madrid, the European medical industry came together for clinical data updates, expertise-sharing and advisory guidance. There were six presentations on biosimilars at the event, including those sponsored by biosimilar manufacturers. Consistent across many sessions were four core themes:


>
Read More

Biosimilars: Facing the Hurdles and Opportunities of Therapeutic Oncology

Posted by Tucker Herbert on May 13, 2016 2:49:06 PM

Despite looming patent expirations, exact-copy “generics” are out of reach for breakthrough oncology drugs such as Rituxan, Herceptin, Avastin and Erbitux given the molecular complexity of biologic medicines. The closest achievable replications are called “biosimilars” because they have demonstrated bioequivalence and non-inferiority. While a few biosimilars have been on the market in Europe for a decade, significant skepticism remains, especially in the space of oncology therapeutics, which represents a $25 billion opportunity in annual revenue.


>
Read More